Provention Plans Two-Phase Launch Of Tzield, Pricing Drug Higher Than Expected

 
• By Alaric DeArment

At nearly $194,000, the wholesale acquisition cost for Tzield came in above analysts’ $100,000-$115,000 estimates, but payer pushback is not expected as the drug faces no competition.

Provention won FDA approval for Tzield, its drug to delay onset of stage 3 type 1 diabetes • Source: Shutterstock

More from New Products

More from Scrip